Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-1: Navitoclax + Ruxolitinib in Myelofibrosis
NCT04472598Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of navitoclax in myelofibrosis (MF), sponsored by AbbVie Inc.. Started Sep 2020; status: completed.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04472598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472598.